2 Oct 2026, 08:22
Periodic ReportsMS
ACRACRUX LIMITED
Announcement history available from 1 August 2025
Fromto
24 Sept 2026, 08:29
Securities Administration—
14 Sept 2026, 09:21
Meetings & Governance—
14 Sept 2026, 09:18
Director Interests—
14 Sept 2026, 09:17
Securities Administration—
3 Sept 2026, 09:16
Director Interests—
3 Sept 2026, 09:16
Director Interests—
3 Sept 2026, 09:16
Director Interests—
3 Sept 2026, 09:16
Director Interests—
3 Sept 2026, 09:15
Director Interests—
3 Sept 2026, 09:15
Securities Administration—
3 Sept 2026, 09:08
Securities Administration—
26 Aug 2026, 09:28
Company Administration—
26 Aug 2026, 09:27
Financial ResultsMS
24 Aug 2026, 09:44
Company Administration—
14 Aug 2026, 09:50
Presentations—
13 Aug 2026, 09:31
Securities Administration—
13 Aug 2026, 09:27
Securities Administration—
6 Aug 2026, 09:02
PresentationsMS
31 July 2026, 10:07
Quarterly ReportsMS
29 July 2026, 10:16
Securities Administration—
29 July 2026, 10:12
Securities Administration—
29 July 2026, 10:09
Securities Administration—
24 July 2026, 09:20
Director Interests—
24 July 2026, 09:18
Securities Administration—
21 July 2026, 11:52
Meetings & Governance—
25 June 2026, 15:03
Securities Administration—
15 June 2026, 09:30
Meetings & Governance—
2 June 2026, 14:17
Director Interests—
2 June 2026, 09:23
Director Interests—
2 June 2026, 09:22
Director Interests—
2 June 2026, 09:21
Securities Administration—
2 June 2026, 09:12
Securities Administration—
2 June 2026, 09:12
Securities Administration—
29 May 2026, 12:19
Company UpdateMS
28 May 2026, 09:04
Company UpdateMS
18 May 2026, 09:50
Securities Administration—
18 May 2026, 09:49
Securities Administration—
14 May 2026, 09:26
Periodic ReportsMS
11 May 2026, 10:58
Securities Administration—
11 May 2026, 10:58
Capital RaisingMS
7 May 2026, 08:58
Trading Halt / SuspensionMS
30 Apr 2026, 16:57
Quarterly ReportsMS
28 Apr 2026, 09:56
Company UpdateMS
12 Mar 2026, 10:01
Periodic ReportsMS
26 Feb 2026, 09:59
Securities Administration—
25 Feb 2026, 09:36
Financial ResultsMS
29 Jan 2026, 08:55
Quarterly ReportsMS
12 Dec 2025, 09:26
Mergers & AcquisitionsMS
3 Dec 2025, 11:11
Director Interests—
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 2 Oct 2026, 08:22 | Acrux has received $1.977m RDTI rebate for FY26 | Periodic Reports | MS | 03014 | |
| 24 Sept 2026, 08:29 | Application for quotation of securities - ACR | Securities Administration | — | 06020 | |
| 14 Sept 2026, 09:21 | AGM date, closing date for director nominations | Meetings & Governance | — | 08006 | |
| 14 Sept 2026, 09:18 | Appendix 3Y Brooke | Director Interests | — | 02009 | |
| 14 Sept 2026, 09:17 | Application for quotation of securities - ACR | Securities Administration | — | 06020 | |
| 3 Sept 2026, 09:16 | Appendix 3Y Brooke | Director Interests | — | 02009 | |
| 3 Sept 2026, 09:16 | Appendix 3Y Warmbrunn | Director Interests | — | 02009 | |
| 3 Sept 2026, 09:16 | Appendix 3Y Oldham | Director Interests | — | 02009 | |
| 3 Sept 2026, 09:16 | Appendix 3Y Brumley | Director Interests | — | 02009 | |
| 3 Sept 2026, 09:15 | Appendix 3Y Dobinson | Director Interests | — | 02009 | |
| 3 Sept 2026, 09:15 | Application for quotation of securities - ACR | Securities Administration | — | 06020 | |
| 3 Sept 2026, 09:08 | Application for quotation of securities - ACR | Securities Administration | — | 06020 | |
| 26 Aug 2026, 09:28 | FY26 Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 26 Aug 2026, 09:27 | FY26 Annual Report and Appendix 4E | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 24 Aug 2026, 09:44 | Acrux appoints Chief Medical Officer | Company Administration | — | 12008 | |
| 14 Aug 2026, 09:50 | Webinar invitation for 17 August 2026, 11am | Presentations | — | 14014 | |
| 13 Aug 2026, 09:31 | Application for quotation of securities - ACR | Securities Administration | — | 06020 | |
| 13 Aug 2026, 09:27 | Notification of cessation of securities - ACR | Securities Administration | — | 06027 | |
| 6 Aug 2026, 09:02 | Investor Presentation - Female Testosterone for HSDD | Presentations | MS | 03026 | |
| 31 July 2026, 10:07 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 | |
| 29 July 2026, 10:16 | Cleansing Notice | Securities Administration | — | 06018 | |
| 29 July 2026, 10:12 | Application for quotation of securities - ACR | Securities Administration | — | 06020 | |
| 29 July 2026, 10:09 | Notification regarding unquoted securities - ACR | Securities Administration | — | 06021 | |
| 24 July 2026, 09:20 | Appendix 3Y Dobinson | Director Interests | — | 02009 | |
| 24 July 2026, 09:18 | Application for quotation of securities - ACR | Securities Administration | — | 06020 | |
| 21 July 2026, 11:52 | Results of Meeting | Meetings & Governance | — | 08003 | |
| 25 June 2026, 15:03 | Application for quotation of securities - ACR | Securities Administration | — | 06020 | |
| 15 June 2026, 09:30 | Notice of Extraordinary General Meeting/Proxy Form | Meetings & Governance | — | 08002, 08004 | |
| 2 June 2026, 14:17 | Appendix 3Y Oldham | Director Interests | — | 02009 | |
| 2 June 2026, 09:23 | Appendix 3Y Dobinson | Director Interests | — | 02009 | |
| 2 June 2026, 09:22 | Appendix 3Y Brumley | Director Interests | — | 02009 | |
| 2 June 2026, 09:21 | Application for quotation of securities - ACR | Securities Administration | — | 06020 | |
| 2 June 2026, 09:12 | Notification of cessation of securities - ACR | Securities Administration | — | 06027 | |
| 2 June 2026, 09:12 | Application for quotation of securities - ACR | Securities Administration | — | 06020 | |
| 29 May 2026, 12:19 | Update - Licensing Lenzetto for Australia for AUD5.4m | Company Update | MS | 11001 | |
| 28 May 2026, 09:04 | Acrux licenses Lenzetto for Australian market for AUD5.4m | Company Update | MS | 11001 | |
| 18 May 2026, 09:50 | Cleansing Notice | Securities Administration | — | 06018 | |
| 18 May 2026, 09:49 | Application for quotation of securities - ACR | Securities Administration | — | 06020 | |
| 14 May 2026, 09:26 | Capital Gains Tax exemptions remain in place for Acrux | Periodic Reports | MS | 03014, 12008 | |
| 11 May 2026, 10:58 | Proposed issue of securities - ACR | Securities Administration | — | 06013 | |
| 11 May 2026, 10:58 | Acrux raises $1.6 million via Share Placement | Capital Raising | MS | 06003, 09014 | |
| 7 May 2026, 08:58 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 30 Apr 2026, 16:57 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19003, 19008 | |
| 28 Apr 2026, 09:56 | Acrux strategy focuses on Female Testosterone for low libido | Company Update | MS | 03026, 11001 | |
| 12 Mar 2026, 10:01 | Acrux receives $0.55m advance on FY26 R&D Tax Incentive | Periodic Reports | MS | 03014, 12008 | |
| 26 Feb 2026, 09:59 | Notification of cessation of securities - ACR | Securities Administration | — | 06027 | |
| 25 Feb 2026, 09:36 | Half Yearly Report and Accounts | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 29 Jan 2026, 08:55 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19002, 19007 | |
| 12 Dec 2025, 09:26 | Divestment of Prilocaine 2.5% and Lidocaine 2.5%, Cream | Mergers & Acquisitions | MS | 07002, 11001 | |
| 3 Dec 2025, 11:11 | Appendix 3Y Warmbrunn | Director Interests | — | 02009 |
1–50 of 72
1 / 2